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Background: Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®,
Biogen) who are planning to become pregnant or discover they are pregnant after exposure to natalizumab are
currently advised to balance the potential benefits and potential risks of exposure when considering treatment
options. This study was undertaken to evaluate pregnancy outcomes of women with MS or CD who were exposed
to natalizumab at any time within 3 months prior to conception or during pregnancy. A pregnancy registry was
created to better understand the effect of natalizumab exposure on pregnancy outcomes.
Methods: The Tysabri Pregnancy Exposure Registry was a global, observational exposure registration and follow-up
study. Evaluations included spontaneous abortions (<22 weeks gestational age), fetal losses (≥22 weeks gestational
age), ectopic pregnancies, elective or therapeutic terminations, stillbirths, birth defects, and live births. Birth defects
were reviewed and coded in accordance with the Metropolitan Atlanta Congenital Defects Program (MACDP)
classification of birth defects.
Results: A total of 369 patients with MS and 7 patients with CD were enrolled prospectively, of whom 355 patients
(99.4 %; 349 MS and 6 CD) had known pregnancy outcomes (including 8 twin sets). The spontaneous abortion rate
was 9.0 % (n = 32; 95 % confidence interval [C. I.], 6.3–12.5 %). An independent advisory committee review
determined the major birth defect rate to be 5.05 % (16 of 316 live births + 1 elective abortion; 95 % C. I., 2.9–8.
1 %). The mean gestational age of the live-born infants was 38.3 weeks, and the mean birth weight was 3158.3 g.
Conclusions: Although the overall rate of birth defects was higher than that observed by the MACDP, these
registry outcomes showed no specific pattern of malformations that would suggest a drug effect, and the
spontaneous abortion rate was consistent with that of the general population.
Trial registration: ClinicalTrials.gov NCT00472992 (11 May 2007).
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Women of childbearing potential comprise a considerable
segment of the patient population affected by multiple
sclerosis (MS) and Crohn’s disease (CD) and may be
exposed to therapies around conception and during
pregnancy. Two-thirds of patients with MS are women,
with a peak onset between 20 and 34 years of age, and ap-
proximately 10 % have disease onset during pregnancy
[1–3]. CD peak onset is between 15 and 35 years of age,
and in some regions there is a slight female predominance
(20–30 % more frequently in women), particularly in
high-incidence areas [4]. Women with MS or CD should
be counseled to balance the benefits and risks of exposure
when considering treatment options before or during
pregnancy [5].
Natalizumab (Tysabri®; Biogen, Cambridge, MA, USA)
is a humanized monoclonal antibody indicated for
relapsing-remitting MS (RRMS) [6] that prevents
leukocyte migration into the brain and reduces inflam-
mation in MS patients [7, 8]. Within the United States,
natalizumab is also approved for treatment of patients
with CD [6]; in CD, natalizumab inhibits leukocyte adhe-
sion and migration into gut tissue [9]. Studies of natali-
zumab in MS have shown reduced relapse rates and
disability progression, but less is known about its effects
on pregnancy outcomes [10, 11]. Natalizumab is classi-
fied as a pregnancy category C drug, as potential fetal ef-
fects have been reported in animal studies [12–14] and
there is a paucity of well-controlled human studies [6].
Although some animal studies have shown that natalizu-
mab can cross the placental barrier and produce
hematologic effects on fetal guinea pigs and primates [6,
12, 14, 15], others have not shown fetal interaction [16].
Human studies and case reports have not shown in-
creases in spontaneous abortions or birth defects; how-
ever, results are limited by small sample sizes [17–20].
This study prospectively evaluated pregnancy outcomes
of women with MS or CD who were exposed to natalizu-




The Tysbari Pregnancy Exposure Registry (TPER; re-
ferred to as the Registry) was a global, observational, ex-
posure registration and follow-up study of pregnant
women with MS or CD. The Registry collected informa-
tion routinely documented in the patient and infant
medical record with no Registry-required interventions
or procedures conducted.
Ethics, consent, and permissions
The Registry (ClinicalTrials.gov NCT00472992) was
established in accordance with regulatory guidance forpregnancy registries [21–23]. Independent ethics
committees (Aspire Institutional Review Board, Santee,
CA, USA, and Institutional Review Board Services,
Auroria, ON, Canada) reviewed and approved this Regis-
try protocol. This study was conducted in accordance
with the ethical principles of Good Clinical Practice
based on the International Conference on Harmonisa-
tion Harmonised Tripartite Guideline. All patients
provided written informed consent and were free to
withdraw participation in the Registry at any time.
Patients
Between February 14, 2007, and April 24, 2011, women
with MS or CD who were exposed to natalizumab at any
time within the 3 months prior to conception or during
pregnancy and for whom the outcome of the pregnancy
was unknown at the time of enrollment were eligible to
be registered prospectively in the study. Patients in-
cluded women enrolled from observational studies
(TYGRIS [Tysabri Global Observational Program in
Safety; NCT00477113 and NCT00483847] or CD IN-
FORM [Crohn’s Disease Investigating Natalizumab
through Further Observational Research and Monitor-
ing; NCT00707512]) or who received natalizumab as a
marketed product in the United States and the rest of
the world (ROW). The Coordinating Center (CC) of the
Registry monitored patients throughout pregnancy and
monitored outcomes within 4 weeks after the estimated
date of delivery (United States and ROW) and within
8–12 weeks post delivery (United States). The CC
point-of-contact and schedule varied slightly based on
the study setting.
Registry data collection
Information was collected about natalizumab exposure,
potential confounding factors (e.g., medical history,
concomitant medications, or smoking), pregnancy out-
comes, spontaneous abortions, fetal losses including
stillbirths, and ectopic pregnancies. In addition, data
were collected for elective or therapeutic pregnancy
terminations, live-born infants, and birth defects.
Birth defects were reviewed and coded by an inde-
pendent birth defect evaluator (a specialist in pediatrics
and genetics) in accordance with the Metropolitan
Atlanta Congenital Defects Program (MACDP) classifi-
cation of birth defects [24]. A major birth defect was
defined as one characterized by a major structural or
chromosomal abnormality in any live or stillborn infant
or electively terminated fetus; any other birth defect was
classified as minor. The MACDP excludes birth defects
that are attributable to prematurity alone or identified
prior to 20 weeks’ gestation. At the end of the study, an
independent scientific advisory committee, consisting
of 3 experts in relevant specialties of teratology,
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ated all Registry outcomes.
Statistical analysis
A target sample size of 300 pregnancy outcomes was
determined based on the ability to detect a 2-fold
increase in spontaneous abortion and a 3-fold increase
in fetal loss and any major birth defects over general
population background rates with 80 % power at the
0.05 level of significance.
For the primary analysis, the major birth defect rate was
calculated by dividing the number of infants with major
birth defects by the total number of live births. Birth defect
rates from the Registry were compared with available back-
ground rates from the MACDP in the US general popula-
tion [25]. A further calculation of the birth defect rate was
performed excluding those birth defects that were consid-
ered to be non-major defects by the MACDP [25]. The rate
of spontaneous abortions was calculated by dividing the
number of fetal losses at <22 weeks gestational age by the
total number of pregnancies. Corresponding 95 % confi-
dence intervals (C. I.s) were calculated for major birth de-
fect and spontaneous abortion rates. Spontaneous abortion
rates in the Registry were compared with general popula-
tion rates reported in published literature [26–28].
Results
Patients
The first patient was enrolled on February 14, 2007, and
the last pregnancy outcome was obtained on April 24,
2012. A total of 376 patients were prospectively enrolled



















Fig. 1 Patients enrolled and outcome of pregnancy. aEight completed pregStates (TYGRIS, n = 19; CD INFORM, n = 2; non-study,
n = 297) and 58 enrolled in the ROW (TYGRIS, n = 58).
The majority of patients had MS; only 7 of 376 patients
had CD. Of the 376 patients, 6 (1.6 %) withdrew consent
and 15 (4.0 %) were lost to follow-up; 355 (94.4 %) pa-
tients (including 8 sets of twins) had known pregnancy
outcomes, resulting in a total of 363 known outcomes
(Fig. 1).
The mean age of the study population was 30.4 years
(standard deviation [SD], 5.15 years; range 16–45 years).
Race was only collected in patients enrolled in the
United States (N = 318). Of US patients enrolled, 73.3 %
were White, 16.4 % were Black, 6.6 % were Hispanic,
and 0.9 % were Asian. Of the 9 patients (2.8 %) listed as
“other”, 3 identified as biracial and 1 patient each as
European, Multi, Filipino, Persian, Middle Eastern, and
unknown.
Maternal obstetric history and prenatal natalizumab use
The maternal characteristics of patients at enrollment
are detailed in Table 1. More than half of the patients
(58.8 %) had experienced ≥1 prior pregnancy. Reports of
prior birth defects were rare; 2 patients reported prior
offspring with birth defects/mental handicap. The mean
gestational age at the time of enrollment was 11.8 weeks
(range 3–39 weeks).
Most enrolled patients (n = 366; 97.3 %) had discontin-
ued natalizumab use at the time of enrollment. Of the
376 patients enrolled, 71 (18.9 %) discontinued natalizu-
mab during the 3-month period prior to conception, 288
(76.6 %) discontinued during the first trimester, and 7
(1.9 %) discontinued during the second trimester. SixPatients with known
pregnancy outcomes
(n = 355)a


















nancies resulted in twin births
Table 1 Baseline characteristics of study population (N = 376)
Maternal characteristic n (%)
Age
≤ 20 years 10 (2.7)
> 20 to 30 years 181 (48.1)
> 30 to 40 years 178 (47.3)
> 40 to 50 years 7 (1.9)
Obstetric history
≥ 1 prior pregnancy 221 (58.8)
1 prior pregnancy resulting in fetal stillbirth (≥ 22 weeks) 2 (0.5)
1 prior miscarriage 53 (14.1)
2 prior miscarriages 11 (2.9)
3 prior miscarriages 4 (1.1)
4 prior miscarriages 1 (0.3)
> 4 prior miscarriages 2 (0.5)
> 4 prior pregnancies resulting in fetal stillbirth (≥ 22 weeks) 1 (0.3)
1 prior elective/therapeutic abortion 28 (7.4)
2 prior elective/therapeutic abortions 4 (1.1)
1 prior ectopic pregnancy 3 (0.8)
Concomitant medications
Prenatal vitamins 168 (44.7)
Baclofen 29 (7.7)




Chicken pox 294 (78.2)
Urinary tract infection 135 (35.9)
Abnormal Pap test 109 (29.0)
Gynecological surgery 55 (14.6)
Breathing disorder 46 (12.2)
Sexually transmitted disease 39 (10.4)
Breast cancer 1 (0.3)




Caffeine use 235 (62.5)
Alcohol consumption 70 (18.6)
Tobacco use 59 (15.7)
Illicit drug use 7 (1.2)
aOf patients who reported caffeine, alcohol, tobacco, or illicit drug use at
enrollment, 168 of 235 (71.5 %), 7 of 70 (10.0 %), 25 of 59 (42.4 %), and 1 of 7
(14.3 %), respectively, continued use during pregnancy
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and 1 patients during the first, second, and third trimes-
ters, respectively.Pregnancy outcomes
Birth defects
Of the 363 pregnancy outcomes in 355 patients, 57 birth
defects (minor or major) were confirmed in 30 infants
(including 3 sets of twins) (Tables 2 and 3); of these, 29
were live births and 1 was an elective termination result-
ing from a birth defect. In the case of the elective ter-
mination, natalizumab exposure was during the
3 months prior to conception. Of the 29 live births with
birth defects, all were born to mothers who were last
exposed to natalizumab during preconception or in
the first trimester. More than half of these infants
(n = 17, 58.6 %) were last exposed between gestational
weeks 1 and 4, while the remainder were last exposed
within 90 days prior to the last menstrual period (n = 6,
20.7 %), between 5 and 8 weeks’ gestation (n = 5, 17.2 %),
or between 9 and 13 weeks’ gestation (n = 1, 3.4 %). The
mean age of mothers who had infants with birth defects
was 31.8 years (range 24–45 years).
Of the 57 observed birth defects (Table 3), those
characterized as a major structural or chromosomal
abnormality in a live or stillborn infant or electively
terminated fetus were identified in 25 infants/fetuses out
of 317 cases (316 live births plus 1 elective termination),
leading to an overall rate of major structural or
chromosomal abnormality of 7.9 % (95 % C. I. 5.2–
11.4 %). To facilitate comparison of Registry data with
the birth defect rate calculated by MACDP, a further
calculation of the major birth defect rate was per-
formed to exclude those birth defects not considered
to be major by the MACDP [25]. This resulted in 18 of
317 infants with major birth defects, representing a rate of
5.7 % (95 % C. I. 3.4–8.8 %). Finally, the Advisory
Committee reviewed all available Registry data; of the 18
cases identified as major birth defects using MACDP
criteria, 3 cases of torticollis were considered medically
minor and were excluded. However, 1 case of congenital
hypothyroidism, which had been excluded by MACDP
criteria, was considered by the Committee to be a major
defect and was included. Therefore, the final adjusted rate
of major birth defects, as adjudicated by the Advisory
Committee, was determined in 16 of 317 cases, or 5.05 %
(95 % C. I. 2.90–8.11 %).Birth defects with possible temporal relationship
A birth defect evaluator also assessed confirmed defects
(minor and major) for a possible temporal relationship
to natalizumab exposure. A total of 26 major and minor
defects were judged to have a possible temporal relation-
ship (i.e., the development of the defect and the timing
of natalizumab exposure could not rule out a possible
association), with 16 major defects in 12 infants and 10
minor defects in 7 infants (Table 4).
Table 2 Pregnancy outcome categorized by time of discontinuation of natalizumab









pregnancy (n = 4)
Total
(N = 363)
Spontaneous abortions 0 32 (11.6) 0 0 0 32 (8.8)
Elective termination (fetal defects) 1 (1.4) 0 0 0 0 1 (0.3)
Elective termination (no fetal defects
or unknown)
2 (2.7) 11 (4.0) 0 0 0 13 (3.6)
Stillbirths without fetal defects 1 (1.4) 0 0 0 0 1 (0.3)
Live birth with congenital anomaly 7 (9.6)a 22 (8.0)b 0 0 0 29 (8.0)
Live birth without congenital anomaly 62 (84.9)c 210 (76.4)a 10 (100) 1 (100) 4 (100) 287 (79.1)
aIncludes 2 sets of twins
bIncludes 1 set of twins
cIncludes 3 sets of twins
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Among the 355 pregnancies resulting in 363 known
pregnancy outcomes, mean gestational age at enrollment
was 11.8 weeks (SD, 6.8 weeks; range 3–39 weeks). In
the 32 spontaneous abortions observed, the mean gesta-
tional age at enrollment was 5.5 weeks (SD, 2.0 weeks;
range 4–13 weeks). Thus, the rate of spontaneous abor-
tion (defined as fetal loss prior to 22 weeks’ gestation)
among pregnancies with known outcomes was 9.0 %
(95 % C. I. 6.3–12.5 %). Of the 355 pregnancies with
known outcomes, 339 were enrolled prior to 22 weeks’
gestation; the rate of spontaneous abortion among these
339 pregnancies was 9.4 % (95 % C. I. 6.6–13.1 %). One
stillbirth (0.3 %) was reported, and 14 patients (3.9 %)
had elective terminations, 1 with a birth defect. No ec-
topic pregnancies were reported.
Physical attributes of live born infants
Of the 316 live born infants, 287 (90.8 %) were born with-
out congenital anomaly. There were 148 males (46.8 %)
and 163 females (51.6 %); gender was not recorded for 5 in-
fants (1.6 %). The mean gestational age at birth was
38.3 weeks (range 26–43 weeks). The majority of infants
(267 of 316, 84.5 %) were born at term (≥37 weeks); 48
(15.2 %) were born prematurely, and gestational age at birth
was not recorded for 1 infant (0.3 %). At birth, mean
APGAR (appearance, pulse, grimace, activity, and respir-
ation) scores were 8.0 (range 1–10) at 1 min, 8.9 (range 2–
10) at 5 min, and 9.6 (range 6–10) at 10 min; mean birth
weight was 3161.7 g (95 % C. I. 3099.5–3223.9 g), mean in-
fant length was 49.7 cm (range 34–56 cm), and mean head
circumference was 35.2 cm (range 30–89 cm). Of the 290
singleton births, 22 (7.6 %) resulted in low birth weight,
which compares favorably with that reported by the US
National Center for Health Statistics (6.27 %) for the 2013
rate of low birth weight in singleton births [29].
Discussion
Currently, women with MS or CD being treated with
natalizumab who are planning to become pregnant ordiscover they are pregnant after natalizumab exposure
are advised to balance the potential benefits and poten-
tial risks of exposure when considering treatment op-
tions. Although some patients are able to discontinue
treatment before or during pregnancy, others with more
severe disease may elect to continue treatment. Thus,
this Registry was undertaken to prospectively gather
important information about pregnancy outcomes in
patients exposed to natalizumab. In the Registry, the rate
of reported birth defects in the infants of women ex-
posed to natalizumab during pregnancy was higher than
the 2.67 % observed in the MACDP. No specific pattern
of malformations was seen within the observed birth de-
fects. The rate of spontaneous abortions was consistent
with the general population [26–28].
Natalizumab prevents leukocyte migration by binding
to α4 integrins that are expressed on the surface of
leukocytes [6]. However, reproductive and/or fetal devel-
opment processes may be affected by inhibition of α4
integrins; of particular note are the processes of
fertilization, placental development, embryo implant-
ation, hematopoiesis, and cardiac development [30–35].
Natalizumab has been categorized as a pregnancy cat-
egory C medication based on animal studies showing
transplacental crossing and potential for offspring
effects, such as reduced pup survival in guinea pigs and
mild anemia or reduced platelet count in the fetus of
monkeys [6, 12, 13]. However, no treatment-related
teratogenic effects were observed, including no cardiac
abnormalities observed in any natalizumab study, in
contrast to the published role of α4 in the formation of
the epicardium and consequent cardiac abnormalities in
α4 null mice [12, 16, 34].
Animal studies provide valuable information, but hu-
man studies are also necessary to understand maternal
and neonatal outcomes. Hellwig et al reported no
decreased fetal growth or teratogenicity in 35 patients
who received natalizumab for ≥8 weeks prior to their
last menses and discontinued treatment as soon as they
became aware of the pregnancy [17]. In these patients,
Table 3 All observed major and minor birth defects (per MACDP
criteria [25]) by organ system
Organ system, birth defect Major or minor
birth defect
Number of
events (n = 57)
Musculoskeletal (n = 11)
Plagiocephalya Minor 4
Torticollisa Major 4
Hip dysplasia Major 1
Polydactyly Major 1
Absent right femur Major 1
Cardiovascular (n = 10)
Ventricular septal defectb Major 3
Patent foramen ovalec Minor 2
Atrial shunt Major 1
Patent ductus arteriosusc Minor 1
Supraventricular tachycardia Minor 1
Tetralogy of Fallot Major 1
Tricuspid valve atresia Major 1
Skin (n = 9)
Hemangioma Minor 2
Café-au-lait spot Minor 1
Irregular tragus Minor 1
Mongolian spot Minor 1
Small anterior fontanelle Minor 1
Subcutaneous cyst Minor 1
Unspecified anomaly of nose Major 1
Unspecified anomaly of toes Minor 1
Genital disorders (n = 8)
Chordee Minor 2
Hydrocele Minor 2
Undescended testicle Minor 2
Chordee with hypospadias Major 1
Penile concealment Major 1





Sacral dimple Minor 1
Unspecified agenesis of corpus callosum Major 1
Renal (n = 5)
Hydronephrosis Major 2
Cystic dysplasia Major 1
Renal dilation Minor 1
Vesicoureteral reflux Major 1
Table 3 All observed major and minor birth defects (per MACDP
criteria [25]) by organ system (Continued)
Gastrointestinal (n = 4)
Umbilical hernia Minor 2
Inguinal hernia Minor 1
Tight frenulum Minor 1
Chromosome (n = 1)
Partial trisomy 9d Major 1
Endocrine (n = 1)
Congenital hypothyroidism Minor 1
Metabolic (n = 1)
Phenylketonuria Major 1
Ocular (n = 1)
Disconjugate gaze Major 1
aThree cases of plagiocephaly and 2 cases of torticollis occurred in 2 sets of twins
bNo cases occurred in a premature birth (i.e., <37 weeks)
cOne case occurred in a premature birth (35 weeks 4 days’ gestation)
dMaternal age was 46 years at enrollment
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higher than that observed in the Registry (9.0 %). Of the
remaining 30 patients in their study, 1 underwent an
elective termination, and 29 women birthed 28 healthy
newborns and 1 infant with a hexadactyly defect that
was also captured in this Registry. The average birth
weight in the natalizumab group (3159 g) was within
normal range for full-term infants (i.e., 2500–4000 g
[36]), although slightly lower than that in the group of
pregnant patients with MS who had not been exposed to
disease modifying therapies (3406 g). Additional case
reports by Mattioda et al [19], Totaro et al [20], and
Hoevenaren et al. [18] did not show any abnormalities
in infants at birth and at a 6-week follow-up.
The potential influence of natalizumab exposure at
different gestational time points should be considered.
Case reports by Mattioda et al [19] and Totaro et al.
[20] found that first-trimester exposure to natalizumab
resulted in uncomplicated gestation and neonatal out-
comes (normal fetal growth and full-term delivery).
Houtchens et al reported on 2 patients with natalizumab
exposure during the first 6 weeks of pregnancy, resulting
in 1 healthy infant and 1 miscarriage [15]. Fagius and
Burman reported on a patient with MS who continued
natalizumab treatment throughout the pregnancy, result-
ing in an uncomplicated caesarian delivery at full-term
and a normal infant at an 8-month follow-up [37]. Al-
though few third-trimester exposures to natalizumab
were reported in the Registry, a recent case series of 13
pregnancies in women with aggressive MS observed
hematological abnormalities in 10 of 13 newborns fol-
lowing third-trimester exposure to natalizumab [38].
In the Registry, the majority of patients discontinued
treatment prior to or within the first trimester. The
Table 4 Major and minor birth defects with possible temporal relationshipa to exposure
Major birth defects Minor birth defects Gestational age at last
natalizumab dose
Maternal concomitant medications
Absent right femur NA 4 weeks Azelastine nasal, prenatal vitamins, zolpidem
Anomaly of nose, cystic dysplasia of kidney,
holoprosencephaly
Sandal toe gap, small
anterior fontanelle
3 weeks Methylphenidate, prenatal vitamins
Atrial shunt NA 1 week Heparin sodium, prenatal vitamins





agenesis of corpus callosum
NA 4 days Methylprednisolone sodium succinate,
sertraline hydrochloride
Hydronephrosis NA 5 weeks Levothyroxine, metformin, sertraline
hydrochloride
Penile concealment NA 3 weeks Prenatal vitamins
Polydactyly NA 5 days Folic acid, insulin
Tetralogy of Fallot NA 0 (29 days prior to
LMP)
Duloxetine, prenatal vitamins, topiramate,
trazodone
Torticollis NA 8 weeks Bupropion, methylprednisolone,
pantoprazole, propoxyphene/
acetaminophen, topiramate
Tricuspid valve atresia NA 3 weeks NR
Ventricular septal defect NA 1 day NR
NA Congenital hypothyroidism 4.5 weeks Nitrofurantoin, prenatal vitamins, Rh0(D)
immune globulin, venlafaxine hydrochloride
NA Irregular tragus, umbilical
hernia
11 weeks Prenatal vitamins
NA Mongolian spot 3 weeks Escitalopram, hydrocodone, levothyroxine,
modafinil, prenatal vitamins
NA Sacral dimple, umbilical hernia 5 weeks Prenatal vitamins, valacyclovir
NA Subcutaneous cyst 3 weeks Prenatal vitamins
NA Tight frenulum 3 days Prenatal vitamins, tizanidine
Abbreviations: LMP last menstrual period, NA not applicable, NR not reported
aPotential relevance of the timing of natalizumab exposure to the birth defect(s) was evaluated and coded by the geneticist as “known cause”, “unknown cause”,
“no association”, or “possible association”
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exposed to natalizumab within 3 months prior to con-
ception or within the first trimester, with more than half
exposed between 1 and 4 weeks of gestation. Of the 4
patients who continued natalizumab treatment during
pregnancy, no congenital anomalies were observed in
the resulting 4 live births. Interpretation of the Registry
data is limited by the duration of natalizumab exposure
during pregnancy.
The Registry found no increased risk of pregnancy loss
in pregnancy outcomes among women with natalizumab
exposure compared with rates in the general population.
The spontaneous abortion rate of patients in the Regis-
try (9.0 %) was lower than that observed in the general
population (13.1–15.9 %) [26, 27] and consistent with a
longitudinal study of untreated pregnant women with
MS (9.8 %) [28]. The background rate for spontaneous
abortion is difficult to identify with precision, andspontaneous abortions were not captured prior to
Registry enrollment, which may present a bias resulting
in the underestimation of the true spontaneous abortion
rate. However, this ascertainment bias is common to
both drug exposure and general population pregnancy
registries insofar as spontaneous abortions are most
often reported among recognized pregnancies.
Upon review of Registry pregnancy outcomes, the
Advisory Committee determined that 16 infants among
the 317 (316 live births plus 1 elective termination) had
defects that met criteria for major defects. The Registry
birth defect rate of 5.05 %, as determined by the Advis-
ory Committee, was higher than the 2.67 % published in
the MACDP [25]. No pattern of defects suggestive of an
unusual distribution was observed. Because birth out-
come reference information specific to untreated MS or
CD patient populations is not available, the MACDP
was used as an external reference group. However, use
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without limitations. The MACDP registers birth outcomes
of ≥20 weeks’ gestation with birth defects in metropolitan
Atlanta; therefore, any birth outcomes of <20 weeks’ gesta-
tion are not captured. Additionally, unlike the Registry,
the MACDP is not disease specific, comprises both
healthy and unhealthy pregnancies, and does not target
particular exposures. In contrast, the Registry population
was a carefully monitored population of patients with MS
or CD, which may have increased potential selection and
ascertainment bias.
Registry outcomes can be complicated by potential
biases inherent to the study population and design. Such
biases may result in an overestimate or an underestimate
of the reported risk. For example, the protocol permitted
enrollment of pregnant patients in the Registry after a
prenatal test, as long as testing did not indicate an
abnormality. However, this practice could potentially
bias the results by lowering the overall risks of birth
defects [39]. Other potential factors that might confound
pregnancy outcomes include maternal obstetrical
history; comorbid medical conditions and medications
[40, 41]; lifestyle factors (e.g., smoking or alcohol intake)
[42]; and planned versus unplanned pregnancy [43].
Some caveats to consider when interpreting the Registry
outcomes include differences in natalizumab exposure
duration, differences in pregnancy outcome detection
between the Registry and MACDP, and the absence of a
comparison group of pregnant women with MS who
were not exposed to natalizumab. As noted by the ex-
pert Advisory Committee, there is currently no valid and
stable estimate of spontaneous abortions or major birth
defects among women with MS not treated with
natalizumab. In addition, previous efforts to include a
comparator arm within an MS treatment pregnancy
study have met with enrollment difficulties [44]. Thus, it
is difficult to determine whether the outcomes observed
in this Registry reflected the effects of natalizumab,
underlying MS disease, or other unmeasured conditions.
Conclusions
The Registry prospectively evaluated pregnancy out-
comes in patients treated with natalizumab within
3 months of conception or during pregnancy. The over-
all rate of major birth defects in the Registry was higher
than that reported by the MACDP. No specific pattern
of birth defects was observed that would suggest a drug
effect. The rate of spontaneous abortions was consistent
with the expected background rates observed in the
general population [26–28]. Although not observed in the
Registry, one report has described transient hematological
abnormalities in infants exposed to natalizumab during
the third trimester [38]. The natalizumab prescribing
information indicates that natalizumab should be usedduring pregnancy only if the potential benefit justifies the
potential risk to the fetus [6]; although the Registry has
noted limitations and more research is needed, the find-
ings from the Registry may be informative to clinicians
and patients in weighing potential risks and benefits of
natalizumab exposure during pregnancy.
Acknowledgments
Suzie Webster of ConsignMed, Inc., wrote the first draft of the manuscript based
on input from authors, Morgan C. Hill, PhD, of Infusion Communications revised
the manuscript based on input from authors, and Joshua Safran of Infusion
Communications copyedited and styled the manuscript per journal
requirements. The authors would like to thank Frances Lynn for valuable
contributions to early drafts of the manuscript and the members of the
Advisory Committee (Allen Mitchell [Slone Epidemiology Center, Boston, MA],
Angela Scheuerle [Tesserae Genetics, Dallas, TX], and Jeffrey Wright [Glen
Meade Center for Women’s Heath, Wrightsville Beach, NC]).
Funding
This study was sponsored by Biogen. Statistical analysis was performed by
United BioSource Corporation. Biogen provided funding for writing and
editorial support in the development of this manuscript. Biogen reviewed
and provided feedback on the manuscript to the authors. The authors had
full editorial control of the manuscript and provided their final approval
of all content.
Availability of data and material
To submit a scientific or medical research proposal requesting access to
participant-level data or clinical study reports from the Tysbari Pregnancy
Exposure Registry, please visit the WIRB Copernicus Group Data Request
Center (https://drc.irbnet.org/release/index.html).
Authors’ contributions
Drafting/revising the manuscript for content, including medical writing for
content: SF, SR, GB, LMC, MW. Study concept or design: SR, GB, LMC. Analysis
or interpretation of data: SF, SR, GB. Statistical analysis: MW. Study supervision
or coordination: GB, SR, LMC. Approval of final manuscript for submission/
publication: SF, SR, GB, LMC, MW.
Competing interests




Ethics approval and consent to participate
Independent ethics committees (Aspire Institutional Review Board, Santee,
CA, USA, and Institutional Review Board Services, Auroria, ON, Canada)
reviewed and approved this Registry protocol. All patients provided written
informed consent and were free to withdraw participation in the Registry at
any time.
Author details
1Biogen, Innovation House, 70 Norden Road, Maidenhead, Berkshire SL6 4AY,
UK. 2Biogen, Cambridge, MA, USA.
Received: 29 October 2015 Accepted: 12 August 2016
References
1. Alcalde-Cabero E, Almazán-Isla J, García-Merino A, de Sá J, de Pedro-Cuesta
J. Incidence of multiple sclerosis among European Economic Area
populations, 1985-2009: the framework for monitoring. BMC Neurol.
2013;13:58.
2. Bennett KA. Pregnancy and multiple sclerosis. Clin Obstet Gynecol.
2005;48:38–47.
3. Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, Robertson NP.
Age at onset as a determinant of presenting phenotype and initial relapse
recovery in multiple sclerosis. Mult Scler. 2012;18:45–54.
Friend et al. BMC Neurology  (2016) 16:150 Page 9 of 94. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural
history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.
5. Coyle PK, Christie S, Fodor P, Fuchs K, Giesser B, Gutierrez A, et al. Multiple
sclerosis gender issues: clinical practices of women neurologists. Mult Scler.
2004;10:582–8.
6. Biogen. Tysabri (natalizumab) injection, for intravenous use US prescribing
information. 2015. http://www.tysabri.com/prescribingInfo. Accessed 16 June 2015.
7. Rudick R, Polman C, Clifford D, Miller D, Steinman L. Natalizumab: bench to
bedside and beyond. JAMA Neurol. 2013;70:172–82.
8. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N.
Prevention of experimental autoimmune encephalomyelitis by antibodies
against alpha 4 beta 1 integrin. Nature. 1992;356:63–6.
9. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC,
et al. Natalizumab induction and maintenance therapy for Crohn’s disease.
N Engl J Med. 2005;353:1912–25.
10. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH,
et al. AFFIRM Investigators. A randomized, placebo-controlled trial of
natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
11. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW,
et al. SENTINEL Investigators. Natalizumab plus interferon beta-1a for
relapsing multiple sclerosis. N Engl J Med. 2006;354:911–23.
12. Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in
cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor.
Birth Defects Res B Dev Reprod Toxicol. 2009;86:117–30.
13. Wehner NG, Skov M, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an
alpha4 integrin inhibitor, on fertility in male and female guinea pigs. Birth
Defects Res B Dev Reprod Toxicol. 2009;86:108–16.
14. Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal
development in cynomolgus monkeys following prenatal exposure to
natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod
Toxicol. 2009;86:144–56.
15. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic
considerations. J Neurol. 2013;260:1202–14.
16. Wehner NG, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4
integrin inhibitor, on the development of Hartley guinea pigs. Birth Defects
Res B Dev Reprod Toxicol. 2009;86:98–107.
17. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an
observational study in 35 accidental pregnancies during natalizumab
treatment. Mult Scler. 2011;17:958–63.
18. Hoevenaren IA, de Vries LC, Rijnders RJ, Lotgering FK. Delivery of healthy
babies after natalizumab use for multiple sclerosis: a report of two cases.
Acta Neurol Scand. 2011;123:430–3.
19. Mattioda A, Masera S, Romagnolo A, Matta M, Superti G, Caligiana L, et al.
Healthy baby delivery after conception during natalizumab exposure: a case
report [abstract]. Mult Scler. 2011;17:S455–S6.
20. Totaro R, Rossi M, Casalena A, Carolei A. Pregnancy, delivery, and birth
outcome after natalizumab use for multiple sclerosis: a report of two cases
[abstract]. Mult Scler. 2011;17:S227–S8.
21. Committee for Medicinal Products for Human Use. Guideline on the
exposure to medicinal products during pregnancy: need for post-
authorisation data. . 2005. http://www.ema.europa.eu/docs/en_GB/
document_library/Regulatory_and_procedural_guideline/2009/11/
WC500011303.pdf. Accessed 21 Nov 2014.
22. US Food and Drug Administration. Guidance for industry: establishing
pregnancy exposure registries. 2002. http://www.fda.gov/downloads/
ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133332.pdf.
Accessed 7 Nov 2014.
23. US Food and Drug Administration. Guidance for industry: good
pharmacovigilance practices and pharmacoepidemiologic assessment. 2005.
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/
UCM126834.pdf. Accessed 30 Apr 2015.
24. Correa-Villaseñor A, Cragan J, Kucik J, O’Leary L, Siffel C, Williams L. The
Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects
surveillance at the Centers for Disease Control and Prevention. Birth Defects
Res A Clin Mol Teratol. 2003;67:617–24.
25. Correa A, Cragan JD, Kucik JE, Alverson CJ, Gilboa SM, Balakrishnan R, et al.
Reporting birth defects surveillance data 1968-2003 [published correction
appears in Birth Defects Res A Clin Mol Teratol 2008;82:41-62]. Birth Defects
Res A Clin Mol Teratol. 2007;79:65–186.
26. Anokute CC. Epidemiology of spontaneous abortions—the effect of
previous abortions. J R Soc Health. 1987;107:31–3.27. Jones RK, Kost K. Underreporting of induced and spontaneous abortion in
the United States: an analysis of the 2002 National Survey of Family Growth.
Stud Fam Plann. 2007;38:187–97.
28. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators,
and pregnancy outcome: a prospective observational study. Mult Scler.
2009;15:1037–42.
29. Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Matthews TJ. Births: final
data for 2013. Natl Vital Stat Rep. 2015;64:1–65.
30. Grazioli A, Alves CS, Konstantopoulos K, Yang JT. Defective blood vessel
development and pericyte/pvSMC distribution in alpha 4 integrin-deficient
mouse embryos. Dev Biol. 2006;293:165–77.
31. Kwee L, Baldwin HS, Shen HM, Stewart CL, Buck C, Buck CA, et al. Defective
development of the embryonic and extraembryonic circulatory systems in
vascular cell adhesion molecule (VCAM-1) deficient mice. Development.
1995;121:489–503.
32. Sueoka K, Shiokawa S, Miyazaki T, Kuji N, Tanaka M, Yoshimura Y. Integrins
and reproductive physiology: expression and modulation in fertilization,
embryogenesis, and implantation. Fertil Steril. 1997;67:799–811.
33. Wagner N, Müller W. Functions of alpha 4- and beta 7-integrins in
hematopoiesis, lymphocyte trafficking and organ development. Curr Top
Microbiol Immunol. 1998;231:23–32.
34. Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by alpha 4
integrins are essential in placental and cardiac development. Development.
1995;121:549–60.
35. Fässler R, Meyer M. Consequences of lack of beta 1 integrin gene
expression in mice. Genes Dev. 1995;9:1896–908.
36. Centers for Disease Control and Prevention. Pediatric and Pregnancy:
Nutrition Surveillance System. 2009. http://www.cdc.gov/pednss/what_is/
pednss_health_indicators.htm#birthweight. Accessed 30 Apr 2015.
37. Fagius J, Burman J. Normal outcome of pregnancy with ongoing treatment
with natalizumab. Acta Neurol Scand. 2014;129:e27–e9.
38. Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T,
Elias-Hamp B, et al. Natalizumab use during the third trimester of
pregnancy. JAMA Neurol. 2014;71:891–5.
39. Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected
characteristics of pregnancy drug registries. Teratology. 1999;60:356–64.
40. Kang JH, Chen YH, Lin HC. Comorbidities amongst patients with multiple
sclerosis: a population-based controlled study. Eur J Neurol. 2010;17:1215–9.
41. Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, et al. CIHR Team in
the Epidemiology and Impact of Comomrbidity on Multiple Sclerosis. The
utility of administrative data for surveillance of comorbidity in multiple
sclerosis: a validation study. Neuroepidemiology. 2013;40:85–92.
42. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High
frequency of adverse health behaviors in multiple sclerosis. Mult Scler.
2009;15:105–13.
43. Tsui A, Lee MA. Multiple sclerosis and pregnancy. Curr Opin Obstet Gynecol.
2011;23:435–9.
44. Coyle PK, Sinclair SM, Scheuerle AE, Thorp Jr JM, Albano JD, Rametta MJ.
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a
prospective observational study of birth defects and pregnancy-related
adverse events. BMJ Open. 2014;4:e004536.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
